Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 13/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400462 | 0.81 | RAB9A (0.53) | TLR8TLR7TDP1KMT2ASMN1; SMN2 | |
| SCHEMBL2401158 | 0.80 | RAB9A (0.47) | TLR8TLR7TDP1MEN1LMNA | |
| SCHEMBL5087283 | 0.79 | TLR8 (0.61) | TLR8TLR7 | |
| SCHEMBL2399101 | 0.78 | TLR8 (0.65) | TLR8TLR7 | |
| SCHEMBL2400926 | 0.76 | TLR7 (0.57) | TLR8TLR7 | |
| SCHEMBL2399936 | 0.75 | TLR8 (0.56) | TLR8TLR7 | |
| SCHEMBL2401299 | 0.75 | TLR8 (0.60) | TLR8TLR7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12269842 | 0.74 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL2400670 | 0.74 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL5090217 | 0.72 | TLR8 (0.57) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2006009826-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | IL2, TSLP, IFNG | TLR8 82/4885TLR7 37/4885SLC6A4 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.